



(51) International Patent Classification:

C07K 5/02 (2006.01) A61K 47/68 (2017.01)

C07K 16/00 (2006.01)

(21) International Application Number:

PCT/US2021/012364

(22) International Filing Date:

06 January 2021 (06.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/957,780 06 January 2020 (06.01.2020) US

(71) Applicant: CYTOMX THERAPEUTICS, INC.

[US/US]; 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (US).

(72) Inventors: SCHLEYER, Siew; C/o Cytomx Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (US). MENDELSON, Brian, A.; C/o Cytomx Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (US). CHALLITA-ED, Pia; C/o Cytomx Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (US). JACKSON, Dowdy; C/o Cy-

tomx Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (US). KEMBALL, Christopher; C/o Cytomx Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (US).


(74) Agent: SHIN, Tae Bum; Cytomx Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), Latin American (AR, BR, CL, CO, CR, CU, EC, EG, ES, FI, FR, GB, GR, GT, HN, ID, IL, IN, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW).

(54) Title: AURISTATIN-RELATED COMPOUNDS, CONJUGATED AURISTATIN-RELATED COMPOUNDS, AND METHODS OF USE THEREOF

Figure 1



(57) Abstract: The invention relates generally to novel compounds of the auristatin family, to novel linkers for coupling a payload to another molecule, such a target-binding molecule, to novel linker-toxin molecules, and to novel antibody molecules that allow controlled, site-specific conjugation.

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*